Advice
in the absence of a submission from the holder of the marketing authorisation:
vildagliptin/metformin hydrochloride (Eucreas®) is not recommended for use within NHS Scotland.
Indication under review: Treatment of type 2 diabetes mellitus:
- in combination with a sulphonylurea (i.e. triple combination therapy) as an adjunct to diet and exercise in patients inadequately controlled with metformin and a sulphonylurea
- in triple combination therapy with insulin as an adjunct to diet and exercise to improve glycaemic control in patients when insulin at a stable dose and metformin alone do not provide adequate glycaemic control
The holder of the marketing authorisation has not made a submission to SMC regarding this product in these indications. As a result we cannot recommend its use within NHSScotland.
Download detailed advice79KB (PDF)
Medicine details
- Medicine name:
- vildagliptin / metformin hydrochloride (Eucreas®)
- SMC ID:
- 874/13
- Indication:
- Treatment of type 2 diabetes mellitus: in combination with a sulphonylurea (i.e. triple combination therapy) as an adjunct to diet and exercise in patients inadequately controlled with metformin and a sulphonylurea - in triple combination therapy with insulin as an adjunct to diet and exercise to improve glycaemic control in patients when insulin at a stable dose and metformin alone do not provide adequate glycaemic control.
- Pharmaceutical company
- Novartis Pharmaceuticals UK Ltd
- BNF chapter
- Endocrine system
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 13 May 2013